| CFI-400945orally available, selective inhibitor of polo-like kinase 4 (PLK4) |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
CFI-400945 Dilution Calculator
calculate
CFI-400945 Molarity Calculator
calculate
| Cas No. | 1338800-06-8; 1338806-73-7 | SDF | Download SDF |
| Chemical Name | (1S,2R)-2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5"-methoxy-spiro[cyclopropane-1,3"-[3H]indol]-2"(1"H)-one | ||
| Canonical SMILES | C[C@@H]1O[C@H](C)CN(CC2=CC=C(/C=C/C3=NNC4=C3C=CC([C@H]5[C@@]6(C(C=C(OC)C=C7)=C7NC6=O)C5)=C4)C=C2)C1 | ||
| Formula | C33H34N4O3 | M.Wt | 534.7 |
| Solubility | ≤12mg/ml in ethanol;10mg/ml in DMSO;20mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
CFI-400945 is an orally active, potent and selective inhibitor of polo-like kinase 4.
Polo-like kinase 4 (PLK4), a unique member of the Polo-like family of kinases, shares little homology with other polo-like kinases. PLK4 plays an essential role in centriole duplication. Overexpression of PLK4 overrides the centriole licensing mechanism and results in centriole amplification with multiple procentrioles forming around each parental centriole. Depletion of PLK4 by RNAi prevents the formation of abnormal centrioles and microtubule-based structures, causing mitotic defects and in some cell lines it can induce apoptosis [2].
In an assay using recombinant human PLK4, CFI-400945 inhibited PLK4 with an IC50 value of 2.8 ± 1.4 nM in an ATP competitive manner with a Ki value of 0.26 ± 0.1 nM. CFI-400945 inhibited autophosphorylation of PLK4 at serine 305 with an EC50 value of 12.3 nM in cells overexpressing PLK4 [1]. CFI-400945 showed no significant inhibitory activity against other PLK family members (PLK1, PLK2, and PLK3 with the IC50s of > 50 μM. In transfected HCT116 cells with TRKA, TRKB, and Tie2/TEK, the EC50 values were 84 nM, 88 nM, and 117 nM, respectively. CFI-400945 inhibited the activity of AURKA and AURKB with the EC50 value of 510 nM and 102 nM. CFI-400945 (≥ 200 nM) decreased the mean centriole number in asynchronous U2OS cells [1]. CFI-400945 inhibited a panel of breast cancer cell growth with the GI50 of 14-165 nM. In mice, the maximum tolerated dose (MTD) of CFI-400945 for once-daily oral administration was estimated to be 7.5-9.5 mg/kg [1].
References:[1] Mason J M, Lin D C C, Wei X, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent[J]. Cancer Cell, 2014, 26(2): 163-176.[2] Sillibourne J E, Bornens M. Polo-like kinase 4: the odd one out of the family[J]. Cell division, 2010, 5(1): 25.
